mRNK-therapy

Methods involving the use of matrix ribonucleic acids (mRNA) are considered one of the most promising in terms of creating drugs for severe diseases, including malignancies.

mRNA acts as instructions for the body's cells, allowing them to create a specific protein.

For mRNA-based vaccines, such directives encode the production of antigen - a pathogen particle that induces an immune response without risk of infection. The main difference between these vaccines and others is that they do not contain the virus itself. The antigen is excreted on the cell surface so that T lymphocytes can recognize it and give directions to other immune cells. As a result, an immune response is initiated.

History

2024: Global mRNA Therapy Market Size Reaches $8.91 Billion

In 2024, costs in the global mRNA therapy market reached $8.91 billion. More than a third of global spending was in the North American region. This is stated in the Fortune Business Insights review, which Zdrav.Expert reviewed at the end of July 2025.

𝓲

Фото: Freepik

The research says that advances in biotechnology are contributing to the industry, including the successful use of the mRNA method in vaccine development during the COVID-19 pandemic. mRNA vaccines do not contain live virus and therefore cannot cause disease. In addition, mRNA does not interact with human DNA and degrades rapidly in the body, which eliminates the possibility of genetic changes. Among the key advantages of mRNA technology, experts include high efficiency in the prevention of severe diseases, reduced development time, adaptability to various strains and pathogens.

The promising direction of the use of mRNA technologies is the development and creation of personalized vaccines to combat cancer. Based on the genetic analysis of the tumor tissue sample of a particular patient, a unique vaccine is created that can instruct the immune system to recognize cancer cells. This increases the effectiveness of therapy.

One of the main factors restraining the growth of the mRNA therapy market is the high cost of manufacturing the corresponding drugs. This process requires a laborious multi-stage cleaning process. Scaling the release of such drugs while ensuring quality and managing logistics faces certain obstacles. Many countries with limited health resources lack the necessary infrastructure to implement mass vaccination programs - this is holding back the introduction of mRNA-based drugs.

By type of mRNA agents, the market is segmented into preventive (vaccines) and drug products. The first of these sectors provided the largest share of revenue in 2024. In terms of application, infectious diseases, oncological ailments, etc., are distinguished. The main revenue was brought by the infectious area. Geographically, North America leads with a share of 35.12%, or $3.13 billion. The Asia-Pacific region is showing the highest growth rates, where there has been a steady increase in investment in the research and development of mRNA drugs. Globally, significant players are named:

• Moderna;
• BioNTech;
• Pfizer;
• CureVac SE;
• GSK;
• Sanofi;
• Omega Therapeutics;
• Strand Therapeutics;
• Immunomic Therapeutics.

In 2025, the mRNA therapy market size is expected to reach $6 billion. Fortune Business Insights analysts believe that in the future, the CAGR will be 19.9%. Thus, by 2032, expenses could increase to $21.45 billion^[1]

Notes